Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	â?¢ To assess the safety of COVID-19 Antiserum when administered as three doses; 24 hours apart; in adult patients aged 18-45 years with SARS-COV-2/COVID- 19 disease.Timepoint: Through Day 28/EOS	â?¢ To assess the safety of COVID-19 Antiserum when administered as three doses; 24 hours apart; in adult patients aged 18-45 years with SARS-COV-2/COVID- 19 disease.Timepoint: Through Day 28/EOS
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Sept. 8, 2021, 1:30 a.m.	oms	â?¢ To assess the safety of COVID-19 Antiserum when administered as three doses; 24 hours apart; in adult patients aged 18-45 years with SARS-COV-2/COVID- 19 disease.Timepoint: Through Day 28/EOS	â?¢ To assess the safety of COVID-19 Antiserum when administered as three doses; 24 hours apart; in adult patients aged 18-45 years with SARS-COV-2/COVID- 19 disease.Timepoint: Through Day 28/EOS